



## Supplementary Materials: Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation

Martina Durcik, Žiga Skok, Janez Ilaš, Nace Zidar, Anamarija Zega, Petra Éva Szili, Gábor Draskovits, Tamás Révész, Danijel Kikelj, Akos Nyerges, Csaba Pál, Lucija Peterlin Mašič and Tihomir Tomašič

## 1. Enzyme Inhibition Graphs

Dose-response curves for six hybrids active against *E. coli* DNA gyrase in supercoiling assay (Figure S1) and for four hybrids active against *E. coli* topoisomerase IV in relaxation assay (Figure S2), shown for an independent measurement. The IC<sub>50</sub> (mean  $\pm$ SD) is the result of at least two independent measurements.



Figure S1. Dose-response curves for compounds 3a, 3b, 7a, 7b, 11a, and 11b for *E. coli* DNA gy-rase.



Figure S2. Dose-response curves for compounds 3a, 7a, 7b, and 11b for *E. coli* topoisomerase IV.



## 2. <sup>1</sup>H NMR Spectra and HPLC Chromatograms of Final Compounds





Figure S4. HPLC chromatogram of compound 3a.



Figure S5. <sup>1</sup>H NMR spectra of compound 3b.







Figure S7. <sup>1</sup>H NMR spectra of compound 7a.



Figure S8. HPLC chromatogram of compound 7a.



Figure S9. <sup>1</sup>H NMR spectra of compound 7b.







Figure S11. <sup>1</sup>H NMR spectra of compound 11a.



Figure S12. HPLC chromatogram of compound 11a.



Figure S13. <sup>1</sup>H NMR spectra of compound 11b.



Figure S14. HPLC chromatogram of compound 11b.